Harry P Erba (Harry Erba)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Topics

Newly Diagnosed

Ejection Fraction

Acute Lymphoblastic Leukemia

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Lyndsay N Harris, Charles David Blanke, Harry P Erba, James M Ford, Robert J Gray, Michael L LeBlanc, Siwen Hu-Lieskovan, Mark R Litzow, Selina M Luger, Funda Meric-Bernstam, Peter J O'Dwyer, Megan K D Othus, Katerina Politi, Lois E Shepherd, Carmen J Allegra, Helen X Chen, Susan Percy Ivy, Larissa A Korde, Richard F Little, Lisa Meier McShane, Jeffrey A Moscow, David R Patton, Magdalena Thurin, Laura M Yee, James H Doroshow
The New NCI Precision Medicine Trials. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sara Zarnegar, Todd Alonzo, Robert B Gerbing, Megan Othus, Zhuoxin Sun, Rhonda E Ries, Jim Wang, Amanda R Leonti, Matthew A Kutny, Fabiana Ostronoff, Jerald P Radich, Frederick R Appelbaum, Era L Pogosova-Agadjanyan, Kristen M O'Dwyer, Martin S Tallman, Mark R Litzow, Ehab Atallah, Todd M Cooper, Richard Aplenc, Omar I Abdel-Wahab, Alan S Gamis, Selina M Luger, Harry P Erba, Ross L Levine, E Anders Kolb, Derek L Stirewalt, Soheil Meshinchi, Katherine Tarlock
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, ECOG analysis. Blood advances (2023)
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan M O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Christine Zhang, Steven E Coutre, Paul M Barr, Amanda F Cashen, Anthony R Mato, Avina K Singh, Michael P Mullane, Richard F Little, Harry P Erba, Richard M Stone, Mark R Litzow, Martin Tallman, Neil E Kay
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140 (2) (2022)
Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David Claxton, Matthew C Foster, Frederick R Appelbaum, Harry P Erba, Mark R Litzow, Martin S Tallman, Richard M Stone, Richard A Larson, Anjali S Advani, Wendy Stock, Selina M Luger
The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study. Blood advances (2022)
Anjali S Advani, Anna B Moseley, Kristen M O'Dwyer, Brent L Wood, Min Fang, Matthew J Wieduwilt, Ibrahim Aldoss, Jae H Park, Rebecca B Klisovic, Maria R Baer, Wendy Stock, Rupali R Bhave, Megan K D Othus, Richard C Harvey, Cheryl L Willman, Mark R Litzow, Richard M Stone, Elad Sharon, Harry P Erba
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (14) (2022)
Anjali S Advani, Anna B Moseley, Kristen M O'Dwyer, Brent L Wood, Jae H Park, Matthew J Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron T Gerds, Susan M O'Brien, Jane L Liesveld, Megan Othus, Mark R Litzow, Richard M Stone, Elad Sharon, Harry P Erba
Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia. Blood advances (2022)
Lori S Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S Advani, Selina M Luger, Martin S Tallman, Mark R Litzow, Matthew C Foster, Harry P Erba, Frederick R Appelbaum, Richard A Larson, Theresa H M Keegan, Wendy Stock
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood advances 6 (14) (2022)
Victoria Wang, Curtis A Hanson, Renee Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta, Susan M O'Brien, Jacqueline Barrientos, Jose F Leis, Cong Christine Zhang, Steven E Coutre, Paul M Barr, Amanda F Cashen, Anthony R Mato, Avina K Singh, Michael P Mullane, Harry P Erba, Richard M Stone, Mark R Litzow, Martin S Tallman, Tait D Shanafelt, Neil E Kay
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib. Blood (2021)
Aziz Nazha, Rami S Komrokji, Manja Meggendorfer, Xuefei Jia, Nathan Radakovich, Jacob Shreve, C Beau Hilton, Yasunubo Nagata, Betty K Hamilton, Sudipto Mukherjee, Najla Al Ali, Wencke Walter, Stephan Hutter, Eric Padron, David A Sallman, Teodora Kuzmanovic, Cassandra Kerr, Vera Adema, David P Steensma, Amy Dezern, Gail J Roboz, Guillermo Garcia Manero, Harry P Erba, Claudia Haferlach, Jaroslaw P Maciejewski, Torsten Haferlach, Mikkael A Sekeres
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (33) (2021)
Harry P Erba, Pamela S Becker, Paul J Shami, Michael R Grunwald, Donna L Flesher, Min Zhu, Erik Rasmussen, Haby A Henary, Abraham A Anderson, Eunice S Wang
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood advances 3 (13) (2020)